788 related articles for article (PubMed ID: 26039720)
1. Biosimilars in inflammatory bowel disease: ready for prime time?
Gomollón F
Curr Opin Gastroenterol; 2015 Jul; 31(4):290-5. PubMed ID: 26039720
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: are they bioequivalent?
Gomollón F
Dig Dis; 2014; 32 Suppl 1():82-7. PubMed ID: 25531357
[TBL] [Abstract][Full Text] [Related]
3. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in inflammatory bowel disease.
Gargallo CJ; Lué A; Gomollón F
Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in the therapy of inflammatory bowel diseases.
Hlavaty T; Letkovsky J
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
[TBL] [Abstract][Full Text] [Related]
6. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
Reinisch W; Louis E; Danese S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
8. Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
Buer L; Høivik ML; Medhus AW; Moum B
Dig Dis; 2017; 35(1-2):74-82. PubMed ID: 28147370
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
[TBL] [Abstract][Full Text] [Related]
10. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
Annese V; Vecchi M;
Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
[TBL] [Abstract][Full Text] [Related]
11. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
Bokemeyer B; Dignaß A; Schreiber S
Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
[TBL] [Abstract][Full Text] [Related]
12. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
13. The use of biosimilars in paediatric inflammatory bowel disease.
Jongsma MME; Vulto A; de Ridder L
Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
Gecse KB; Lakatos PL
Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
[TBL] [Abstract][Full Text] [Related]
15. A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.
Ha CY; Kornbluth A
Inflamm Bowel Dis; 2016 Oct; 22(10):2513-26. PubMed ID: 27564646
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory diseases: Integrating biosimilars into clinical practice.
Feldman SR
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
[TBL] [Abstract][Full Text] [Related]
17. Experience with Biosimilar Infliximab (Remsima®) in Norway.
Jahnsen J; Kaasen Jørgensen K
Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in IBD: from theory to practice.
Danese S; Bonovas S; Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
[TBL] [Abstract][Full Text] [Related]
19. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
